- Home
- BHVN vs ARQT Comparison
BHVN vs ARQT Comparison
Compare BHVN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHVN
- ARQT
- Stock Information
- Founded
- BHVN 2013
- ARQT 2016
- Country
- BHVN United States
- ARQT United States
- Employees
- BHVN N/A
- ARQT N/A
- Industry
- BHVN Biotechnology: Pharmaceutical Preparations
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- BHVN Health Care
- ARQT Health Care
- Exchange
- BHVN Nasdaq
- ARQT Nasdaq
- Market Cap
- BHVN 1.9B
- ARQT 1.7B
- IPO Year
- BHVN 2017
- ARQT 2020
- Fundamental
- Price
- BHVN $20.24
- ARQT $13.53
- Analyst Decision
- BHVN Strong Buy
- ARQT Strong Buy
- Analyst Count
- BHVN 14
- ARQT 6
- Target Price
- BHVN $62.92
- ARQT $18.80
- AVG Volume (30 Days)
- BHVN 2.2M
- ARQT 2.1M
- Earning Date
- BHVN 05-16-2025
- ARQT 05-06-2025
- Dividend Yield
- BHVN N/A
- ARQT N/A
- EPS Growth
- BHVN N/A
- ARQT N/A
- EPS
- BHVN N/A
- ARQT N/A
- Revenue
- BHVN N/A
- ARQT $212,819,000.00
- Revenue This Year
- BHVN N/A
- ARQT $57.99
- Revenue Next Year
- BHVN $65.26
- ARQT $41.24
- P/E Ratio
- BHVN N/A
- ARQT N/A
- Revenue Growth
- BHVN N/A
- ARQT 100.03
- 52 Week Low
- BHVN $15.79
- ARQT $6.99
- 52 Week High
- BHVN $55.70
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- BHVN 43.79
- ARQT 42.73
- Support Level
- BHVN $18.75
- ARQT $12.42
- Resistance Level
- BHVN $24.06
- ARQT $15.67
- Average True Range (ATR)
- BHVN 2.00
- ARQT 0.84
- MACD
- BHVN 0.21
- ARQT -0.07
- Stochastic Oscillator
- BHVN 42.39
- ARQT 34.15
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.